Product Details
Cyclophosphamide + Methotrexate + Fluorouracil, CMF Oral, for Tablets BP — Standard
Product Name
:
Cyclophosphamide + Methotrexate + Fluorouracil, CMF Oral, for Tablets BP — Standard
Brand Name
:
VEROCMF
Available Strength
:
Cyclophosphamide BP 50 mg + Methotrexate BP 2.5 mg + Fluorouracil BP 500 mg
Packing
:
60 Tablets
Pack Insert/Leaflet
:
According To Your Needs
This oral formulation follows the established CMF regimen, a chemotherapy combination used in breast cancer treatment. Oncologists prescribe CMF-based therapy under close supervision, with dosing and cycling tailored to each patient.
The tablets combine:
- Cyclophosphamide BP (50 mg) — an alkylating agent that interferes with DNA replication in rapidly dividing cancer cells
- Methotrexate BP (2.5 mg) — an antimetabolite that inhibits folic acid metabolism, disrupting DNA and RNA synthesis in cancer cells
- Fluorouracil BP (500 mg) — an antimetabolite that blocks thymidylate synthase, interfering with DNA synthesis in rapidly dividing cells
Together, these three agents target cancer cell replication through complementary mechanisms. Oncology specialists administer CMF-based regimens under strict clinical protocols, with dosing individualized to each patient’s treatment plan.
Key Features
- Formulated to BP (British Pharmacopoeia) standards
- Combines three chemotherapy agents in a single oral dosage form
- Manufactured under GMP-compliant, high-alert medication handling protocols
- Intended strictly for use under oncology specialist supervision
- Requires careful storage and containment given its cytotoxic nature
- Restricted to hospital, oncology clinic, and specialist institutional supply